- Home
- MARPS vs LGVN Comparison
MARPS vs LGVN Comparison
Compare MARPS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- LGVN
- Stock Information
- Founded
- MARPS 1956
- LGVN 2014
- Country
- MARPS United States
- LGVN United States
- Employees
- MARPS N/A
- LGVN N/A
- Industry
- MARPS Oil & Gas Production
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- MARPS Energy
- LGVN Health Care
- Exchange
- MARPS Nasdaq
- LGVN Nasdaq
- Market Cap
- MARPS 7.9M
- LGVN 30.0M
- IPO Year
- MARPS N/A
- LGVN 2021
- Fundamental
- Price
- MARPS $4.10
- LGVN $2.05
- Analyst Decision
- MARPS
- LGVN Strong Buy
- Analyst Count
- MARPS 0
- LGVN 2
- Target Price
- MARPS N/A
- LGVN $8.00
- AVG Volume (30 Days)
- MARPS 29.2K
- LGVN 393.9K
- Earning Date
- MARPS 01-01-0001
- LGVN 11-08-2024
- Dividend Yield
- MARPS 8.19%
- LGVN N/A
- EPS Growth
- MARPS N/A
- LGVN N/A
- EPS
- MARPS 0.36
- LGVN N/A
- Revenue
- MARPS $1,044,997.00
- LGVN $1,229,000.00
- Revenue This Year
- MARPS N/A
- LGVN $161.78
- Revenue Next Year
- MARPS N/A
- LGVN $8.62
- P/E Ratio
- MARPS $11.36
- LGVN N/A
- Revenue Growth
- MARPS N/A
- LGVN 39.34
- 52 Week Low
- MARPS $3.77
- LGVN $0.77
- 52 Week High
- MARPS $6.50
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- MARPS 49.68
- LGVN 52.20
- Support Level
- MARPS $3.98
- LGVN $1.76
- Resistance Level
- MARPS $4.19
- LGVN $2.26
- Average True Range (ATR)
- MARPS 0.20
- LGVN 0.12
- MACD
- MARPS -0.02
- LGVN 0.05
- Stochastic Oscillator
- MARPS 14.63
- LGVN 58.00
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.